Equity Profile

INCY

Incyte Corporation

Health CareBiotechnology$20.5B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Incyte Corporation is a biotechnology company focused on developing innovative medicines for cancer and other serious diseases. With a market cap of $19 billion, it operates in the health care sector, which is increasingly important as the demand for effective treatments continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and indicates demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

In Q1 2026, Incyte reported an EPS of $1.81, significantly beating expectations by 58.77%. The stock reacted positively, increasing by 2.12% the following day.

Management Promises & Guidance

Continue to advance clinical trials for key drug candidates.
Focus on expanding market access for existing products.
Enhance operational efficiency to improve profit margins.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent strong performance. However, there is uncertainty about future revenue growth and pipeline developments.

Bull Case

If Incyte can demonstrate strong revenue growth and positive updates on its drug pipeline, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's market performance and future potential, especially given recent strong EPS results.

What updates can be provided on the drug pipeline and clinical trials?

Progress in the pipeline can significantly influence investor confidence and stock performance, making this a key area of focus.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Incyte's ability to leverage its recent drug approvals for significant revenue growth this quarter.

Supporting Evidence

The company has a strong track record of beating EPS estimates, suggesting potential for positive surprises.

Recent insider selling could indicate a strategic shift rather than a lack of confidence in the company's future.

Options pricing suggests a higher expected volatility, which may reflect underlying confidence in upcoming announcements.

Key Risk

If revenue growth exceeds 15%, it could challenge the cautious consensus and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth and successfully advance its drug pipeline amid competitive pressures.

Bull Confirmed If

Demonstrating revenue growth of at least 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or negative updates on the drug pipeline would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.8M

18,667 sh

1 insider

Net

$1.8M

Net selling

Most Active Insiders· 1 open-market trade

President, Global Head of R&DCAGNONI PABLO J
$1.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests a potential stock increase of around 1.13%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of 0.18% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth expectations for the upcoming quarter.
2Details on the progress of key drug candidates in the pipeline.
3Any changes to operational efficiency strategies.
4Insights into market access strategies for existing products.
5Management's outlook on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and indicates demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

In Q1 2026, Incyte reported an EPS of $1.81, significantly beating expectations by 58.77%. The stock reacted positively, increasing by 2.12% the following day.

Management Promises & Guidance

Continue to advance clinical trials for key drug candidates.
Focus on expanding market access for existing products.
Enhance operational efficiency to improve profit margins.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent strong performance. However, there is uncertainty about future revenue growth and pipeline developments.

Bull Case

If Incyte can demonstrate strong revenue growth and positive updates on its drug pipeline, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is crucial for assessing the company's market performance and future potential, especially given recent strong EPS results.

What updates can be provided on the drug pipeline and clinical trials?

Progress in the pipeline can significantly influence investor confidence and stock performance, making this a key area of focus.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Incyte's ability to leverage its recent drug approvals for significant revenue growth this quarter.

Supporting Evidence

The company has a strong track record of beating EPS estimates, suggesting potential for positive surprises.

Recent insider selling could indicate a strategic shift rather than a lack of confidence in the company's future.

Options pricing suggests a higher expected volatility, which may reflect underlying confidence in upcoming announcements.

Key Risk

If revenue growth exceeds 15%, it could challenge the cautious consensus and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth and successfully advance its drug pipeline amid competitive pressures.

Bull Confirmed If

Demonstrating revenue growth of at least 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or negative updates on the drug pipeline would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.8M

18,667 sh

1 insider

Net

$1.8M

Net selling

Most Active Insiders· 1 open-market trade

President, Global Head of R&DCAGNONI PABLO J
$1.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests a potential stock increase of around 1.13%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of 0.18% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth expectations for the upcoming quarter.
2Details on the progress of key drug candidates in the pipeline.
3Any changes to operational efficiency strategies.
4Insights into market access strategies for existing products.
5Management's outlook on competitive pressures in the biotechnology sector.